Table 1.
Ca2+ channel disease | ||||
---|---|---|---|---|
Type | Pore‐forming subunit (gene) | Gain of function | Loss of function | References |
L‐type | Cav1.1 (CACNA1S) |
|
|
Striessnig et al. 2010 |
Cav1.2 (CACNA1C) |
|
|
Zamponi et al. 2015 | |
Cav1.3 (CACNA1D) |
|
|
Pinggera & Striessnig, 2016 | |
Cav1.4 (CACNA1F) |
|
|
Zamponi et al. 2015 | |
P/Q‐type | Cav2.1 (CACNA1A) |
|
||
N‐type | Cav2.2 (CACNA1B) |
|
|
Mencacci et al. 2015 |
R‐type | Cav2.3 (CACNA1E) |
|
|
Zamponi et al. 2015, 4 |
T‐type | Cav3.1 (CACNA1G) |
|
|
Coutelier et al. 2015 |
Cav3.2 (CACNA1H) |
|
|
Zamponi et al. 2015 | |
Cav3.3 (CACNA1I) |
|
|
Zamponi et al. 2015, 4 |
Autoimmune disorders involving anti‐Ca2+ channel antibodies and diseases caused by genetic defects in associated α2δ‐ and β‐subunits are not listed here (see Zamponi et al. 2015 for a recent review). 1Functional consequences for channel function unclear but likely loss‐of‐function. 2Episodic ataxia may co‐exist with other phenotypes caused by CACNA1A mutations. 3Enhanced neuronal activity predicted in deep cerebellar nuclei. 4See review for mouse knockout phenotypes. Abbreviations: dn, de novo mutation; fam, familial (some may also occur sporadically); ins, in‐frame insertion; lof, loss of function mutation; mis, missense; n.r., not reported; PASNA, primary aldosteronism, seizures and neurological abnormalities; pQex, poly glutamine expansion.